Limits...
Prescription pattern of chinese herbal products for breast cancer in taiwan: a population-based study.

Lai JN, Wu CT, Wang JD - Evid Based Complement Alternat Med (2012)

Bottom Line: Background.Conclusion.CHP containing dang qui (Angelica sinensis-radix) or ren shen (Panax ginseng-radix) are the most frequently prescribed for breast cancer and their effects should be taken into account by healthcare providers.

View Article: PubMed Central - PubMed

Affiliation: Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei City 112, Taiwan.

ABSTRACT
Background. Chinese herbal products (CHPs) given as a therapy for symptom relief have gained widespread popularity among women with breast cancer. The aim of this study was to analyze the utilization of CHP among women with breast cancer in Taiwan. Methods. The usage, frequency of services, and CHP prescribed for breast cancer among women with breast cancer were evaluated, recruited from a randomly sampled cohort of 1,000,000 beneficiaries from the National Health Insurance Research Database. The logistic regression method was employed to estimate the odds ratios (ORs) for utilization of CHP. Results. 81.5 percent (N = 2, 236) of women with breast cancer utilized traditional Chinese medicine (TCM) and 18% of them sought TCM with the intent of treating their breast cancer. Jia-wei-xiao-yao-san (Augmented Rambling Powder) was the most frequently prescribed formula for treating breast cancer. Among the top 10 most frequently prescribed CHP for treating breast cancer, seven contained dang qui (Angelica sinensis-radix) and six contained ren shen (Panax ginseng-radix), which are reported to have potential beneficial synergistic effects on breast cancer cells. Conclusion. CHP containing dang qui (Angelica sinensis-radix) or ren shen (Panax ginseng-radix) are the most frequently prescribed for breast cancer and their effects should be taken into account by healthcare providers.

No MeSH data available.


Related in: MedlinePlus

Flowchart of recruitment of subjects from the 1-million random sample of the National Health Insurance Research Database (NHIRD) from 1999 to 2008 in Taiwan.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3368194&req=5

fig1: Flowchart of recruitment of subjects from the 1-million random sample of the National Health Insurance Research Database (NHIRD) from 1999 to 2008 in Taiwan.

Mentions: The selection of study subjects from the random sample of one million individuals was performed as follows (Figure 1). First, we excluded all male beneficiaries (n = 495, 835) or those with missing information concerning gender (n = 3). Second, female beneficiaries without breast cancer (n = 500, 809) were excluded. Third, the prevalent cases of other cancers (n = 125) and breast cancer (n = 486) diagnosed before the end of 1998 were also excluded to make sure that all the subjects included were newly diagnosed with invasive breast cancer and the diagnosis was verified by the NHI registry of catastrophic illnesses during 1998–2008. All patients who are registered to have a catastrophic illness are exempted from all copayments. To be registered as such, patients must have the diagnosis of invasive breast cancer (ICD-9 code 174) validated by tissue pathology. Finally, 2,742 female subjects were included in the cohort.


Prescription pattern of chinese herbal products for breast cancer in taiwan: a population-based study.

Lai JN, Wu CT, Wang JD - Evid Based Complement Alternat Med (2012)

Flowchart of recruitment of subjects from the 1-million random sample of the National Health Insurance Research Database (NHIRD) from 1999 to 2008 in Taiwan.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3368194&req=5

fig1: Flowchart of recruitment of subjects from the 1-million random sample of the National Health Insurance Research Database (NHIRD) from 1999 to 2008 in Taiwan.
Mentions: The selection of study subjects from the random sample of one million individuals was performed as follows (Figure 1). First, we excluded all male beneficiaries (n = 495, 835) or those with missing information concerning gender (n = 3). Second, female beneficiaries without breast cancer (n = 500, 809) were excluded. Third, the prevalent cases of other cancers (n = 125) and breast cancer (n = 486) diagnosed before the end of 1998 were also excluded to make sure that all the subjects included were newly diagnosed with invasive breast cancer and the diagnosis was verified by the NHI registry of catastrophic illnesses during 1998–2008. All patients who are registered to have a catastrophic illness are exempted from all copayments. To be registered as such, patients must have the diagnosis of invasive breast cancer (ICD-9 code 174) validated by tissue pathology. Finally, 2,742 female subjects were included in the cohort.

Bottom Line: Background.Conclusion.CHP containing dang qui (Angelica sinensis-radix) or ren shen (Panax ginseng-radix) are the most frequently prescribed for breast cancer and their effects should be taken into account by healthcare providers.

View Article: PubMed Central - PubMed

Affiliation: Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei City 112, Taiwan.

ABSTRACT
Background. Chinese herbal products (CHPs) given as a therapy for symptom relief have gained widespread popularity among women with breast cancer. The aim of this study was to analyze the utilization of CHP among women with breast cancer in Taiwan. Methods. The usage, frequency of services, and CHP prescribed for breast cancer among women with breast cancer were evaluated, recruited from a randomly sampled cohort of 1,000,000 beneficiaries from the National Health Insurance Research Database. The logistic regression method was employed to estimate the odds ratios (ORs) for utilization of CHP. Results. 81.5 percent (N = 2, 236) of women with breast cancer utilized traditional Chinese medicine (TCM) and 18% of them sought TCM with the intent of treating their breast cancer. Jia-wei-xiao-yao-san (Augmented Rambling Powder) was the most frequently prescribed formula for treating breast cancer. Among the top 10 most frequently prescribed CHP for treating breast cancer, seven contained dang qui (Angelica sinensis-radix) and six contained ren shen (Panax ginseng-radix), which are reported to have potential beneficial synergistic effects on breast cancer cells. Conclusion. CHP containing dang qui (Angelica sinensis-radix) or ren shen (Panax ginseng-radix) are the most frequently prescribed for breast cancer and their effects should be taken into account by healthcare providers.

No MeSH data available.


Related in: MedlinePlus